nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Paclitaxel—kidney cancer	0.118	0.185	CbGbCtD
Bosentan—ABCB11—Vinblastine—kidney cancer	0.104	0.162	CbGbCtD
Bosentan—ABCB11—Vincristine—kidney cancer	0.102	0.159	CbGbCtD
Bosentan—ABCB11—Doxorubicin—kidney cancer	0.0637	0.0996	CbGbCtD
Bosentan—CYP3A4—Everolimus—kidney cancer	0.0524	0.0819	CbGbCtD
Bosentan—CYP3A4—Temsirolimus—kidney cancer	0.0354	0.0553	CbGbCtD
Bosentan—CYP2C9—Capecitabine—kidney cancer	0.0333	0.0521	CbGbCtD
Bosentan—CYP2C9—Paclitaxel—kidney cancer	0.0209	0.0327	CbGbCtD
Bosentan—CYP3A4—Pazopanib—kidney cancer	0.0186	0.0291	CbGbCtD
Bosentan—CYP2C9—Sorafenib—kidney cancer	0.0185	0.029	CbGbCtD
Bosentan—CYP3A4—Erlotinib—kidney cancer	0.0133	0.0207	CbGbCtD
Bosentan—CYP3A4—Paclitaxel—kidney cancer	0.0121	0.019	CbGbCtD
Bosentan—CYP3A4—Sorafenib—kidney cancer	0.0108	0.0169	CbGbCtD
Bosentan—CYP3A4—Vinblastine—kidney cancer	0.0106	0.0167	CbGbCtD
Bosentan—CYP3A4—Vincristine—kidney cancer	0.0105	0.0164	CbGbCtD
Bosentan—CYP3A4—Sunitinib—kidney cancer	0.00873	0.0137	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—kidney cancer	0.00654	0.0102	CbGbCtD
Bosentan—CYP2C9—urine—kidney cancer	0.000687	0.195	CbGeAlD
Bosentan—EDNRB—cortex of kidney—kidney cancer	0.000579	0.164	CbGeAlD
Bosentan—EDNRB—cardiac atrium—kidney cancer	0.00055	0.156	CbGeAlD
Bosentan—CYP3A4—urine—kidney cancer	0.000524	0.149	CbGeAlD
Bosentan—EDNRA—cortex of kidney—kidney cancer	0.000478	0.136	CbGeAlD
Bosentan—EDNRA—cardiac atrium—kidney cancer	0.000455	0.129	CbGeAlD
Bosentan—CYP3A4—renal system—kidney cancer	0.000128	0.0364	CbGeAlD
Bosentan—CYP3A4—kidney—kidney cancer	0.000124	0.0352	CbGeAlD
Bosentan—Anxiety—Paclitaxel—kidney cancer	0.000114	0.000386	CcSEcCtD
Bosentan—Decreased appetite—Gemcitabine—kidney cancer	0.000114	0.000386	CcSEcCtD
Bosentan—Hypersensitivity—Dactinomycin—kidney cancer	0.000114	0.000386	CcSEcCtD
Bosentan—Chills—Capecitabine—kidney cancer	0.000114	0.000385	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000114	0.000385	CcSEcCtD
Bosentan—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000113	0.000383	CcSEcCtD
Bosentan—Discomfort—Paclitaxel—kidney cancer	0.000113	0.000383	CcSEcCtD
Bosentan—Fatigue—Gemcitabine—kidney cancer	0.000113	0.000383	CcSEcCtD
Bosentan—Gastrointestinal pain—Vincristine—kidney cancer	0.000113	0.000383	CcSEcCtD
Bosentan—Cardiac arrest—Doxorubicin—kidney cancer	0.000112	0.00038	CcSEcCtD
Bosentan—Dizziness—Sorafenib—kidney cancer	0.000112	0.00038	CcSEcCtD
Bosentan—Constipation—Gemcitabine—kidney cancer	0.000112	0.00038	CcSEcCtD
Bosentan—Pain—Gemcitabine—kidney cancer	0.000112	0.00038	CcSEcCtD
Bosentan—Nausea—Erlotinib—kidney cancer	0.000112	0.00038	CcSEcCtD
Bosentan—Dry mouth—Paclitaxel—kidney cancer	0.000112	0.000379	CcSEcCtD
Bosentan—Mood swings—Doxorubicin—kidney cancer	0.000112	0.000379	CcSEcCtD
Bosentan—Diarrhoea—Sunitinib—kidney cancer	0.000112	0.000379	CcSEcCtD
Bosentan—Mental disorder—Capecitabine—kidney cancer	0.000111	0.000376	CcSEcCtD
Bosentan—Asthenia—Dactinomycin—kidney cancer	0.000111	0.000376	CcSEcCtD
Bosentan—Erythema—Capecitabine—kidney cancer	0.00011	0.000374	CcSEcCtD
Bosentan—Malnutrition—Capecitabine—kidney cancer	0.00011	0.000374	CcSEcCtD
Bosentan—Dehydration—Doxorubicin—kidney cancer	0.00011	0.000372	CcSEcCtD
Bosentan—Anaphylactic shock—Paclitaxel—kidney cancer	0.00011	0.000372	CcSEcCtD
Bosentan—Oedema—Paclitaxel—kidney cancer	0.00011	0.000372	CcSEcCtD
Bosentan—Abdominal pain—Vincristine—kidney cancer	0.000109	0.00037	CcSEcCtD
Bosentan—Body temperature increased—Vincristine—kidney cancer	0.000109	0.00037	CcSEcCtD
Bosentan—Liver function test abnormal—Doxorubicin—kidney cancer	0.000109	0.000369	CcSEcCtD
Bosentan—Infection—Paclitaxel—kidney cancer	0.000109	0.000369	CcSEcCtD
Bosentan—Flatulence—Capecitabine—kidney cancer	0.000109	0.000368	CcSEcCtD
Bosentan—Dry skin—Doxorubicin—kidney cancer	0.000108	0.000367	CcSEcCtD
Bosentan—Dizziness—Sunitinib—kidney cancer	0.000108	0.000366	CcSEcCtD
Bosentan—Shock—Paclitaxel—kidney cancer	0.000108	0.000366	CcSEcCtD
Bosentan—Vomiting—Sorafenib—kidney cancer	0.000108	0.000366	CcSEcCtD
Bosentan—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000108	0.000365	CcSEcCtD
Bosentan—Abdominal pain upper—Doxorubicin—kidney cancer	0.000108	0.000365	CcSEcCtD
Bosentan—Nervous system disorder—Paclitaxel—kidney cancer	0.000107	0.000365	CcSEcCtD
Bosentan—Hypokalaemia—Doxorubicin—kidney cancer	0.000107	0.000364	CcSEcCtD
Bosentan—Thrombocytopenia—Paclitaxel—kidney cancer	0.000107	0.000364	CcSEcCtD
Bosentan—Tachycardia—Paclitaxel—kidney cancer	0.000107	0.000363	CcSEcCtD
Bosentan—Rash—Sorafenib—kidney cancer	0.000107	0.000363	CcSEcCtD
Bosentan—Dermatitis—Sorafenib—kidney cancer	0.000107	0.000362	CcSEcCtD
Bosentan—Back pain—Capecitabine—kidney cancer	0.000107	0.000362	CcSEcCtD
Bosentan—Skin disorder—Paclitaxel—kidney cancer	0.000106	0.000361	CcSEcCtD
Bosentan—Headache—Sorafenib—kidney cancer	0.000106	0.00036	CcSEcCtD
Bosentan—Muscle spasms—Capecitabine—kidney cancer	0.000106	0.000359	CcSEcCtD
Bosentan—Hyperhidrosis—Paclitaxel—kidney cancer	0.000106	0.000359	CcSEcCtD
Bosentan—Diarrhoea—Dactinomycin—kidney cancer	0.000106	0.000358	CcSEcCtD
Bosentan—Nasopharyngitis—Doxorubicin—kidney cancer	0.000105	0.000358	CcSEcCtD
Bosentan—Anorexia—Paclitaxel—kidney cancer	0.000104	0.000354	CcSEcCtD
Bosentan—Vision blurred—Capecitabine—kidney cancer	0.000104	0.000352	CcSEcCtD
Bosentan—Vomiting—Sunitinib—kidney cancer	0.000104	0.000352	CcSEcCtD
Bosentan—Body temperature increased—Gemcitabine—kidney cancer	0.000103	0.000351	CcSEcCtD
Bosentan—Tremor—Capecitabine—kidney cancer	0.000103	0.00035	CcSEcCtD
Bosentan—Rash—Sunitinib—kidney cancer	0.000103	0.000349	CcSEcCtD
Bosentan—Dermatitis—Sunitinib—kidney cancer	0.000103	0.000349	CcSEcCtD
Bosentan—Abdominal distension—Doxorubicin—kidney cancer	0.000103	0.000348	CcSEcCtD
Bosentan—Hypotension—Paclitaxel—kidney cancer	0.000102	0.000347	CcSEcCtD
Bosentan—Headache—Sunitinib—kidney cancer	0.000102	0.000347	CcSEcCtD
Bosentan—Asthma—Doxorubicin—kidney cancer	0.000102	0.000346	CcSEcCtD
Bosentan—Influenza—Doxorubicin—kidney cancer	0.000102	0.000346	CcSEcCtD
Bosentan—Anaemia—Capecitabine—kidney cancer	0.000102	0.000346	CcSEcCtD
Bosentan—Hypersensitivity—Vincristine—kidney cancer	0.000102	0.000345	CcSEcCtD
Bosentan—Eosinophilia—Doxorubicin—kidney cancer	0.000101	0.000342	CcSEcCtD
Bosentan—Nausea—Sorafenib—kidney cancer	0.000101	0.000342	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Paclitaxel—kidney cancer	9.99e-05	0.000339	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—kidney cancer	9.93e-05	0.000337	CcSEcCtD
Bosentan—Insomnia—Paclitaxel—kidney cancer	9.91e-05	0.000336	CcSEcCtD
Bosentan—Vertigo—Capecitabine—kidney cancer	9.9e-05	0.000336	CcSEcCtD
Bosentan—Asthenia—Vincristine—kidney cancer	9.9e-05	0.000336	CcSEcCtD
Bosentan—Syncope—Capecitabine—kidney cancer	9.88e-05	0.000335	CcSEcCtD
Bosentan—Leukopenia—Capecitabine—kidney cancer	9.87e-05	0.000335	CcSEcCtD
Bosentan—Paraesthesia—Paclitaxel—kidney cancer	9.84e-05	0.000334	CcSEcCtD
Bosentan—Vomiting—Dactinomycin—kidney cancer	9.82e-05	0.000333	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—kidney cancer	9.81e-05	0.000333	CcSEcCtD
Bosentan—Dyspnoea—Paclitaxel—kidney cancer	9.77e-05	0.000331	CcSEcCtD
Bosentan—Somnolence—Paclitaxel—kidney cancer	9.74e-05	0.000331	CcSEcCtD
Bosentan—Palpitations—Capecitabine—kidney cancer	9.74e-05	0.00033	CcSEcCtD
Bosentan—Rash—Dactinomycin—kidney cancer	9.74e-05	0.00033	CcSEcCtD
Bosentan—Nausea—Sunitinib—kidney cancer	9.69e-05	0.000329	CcSEcCtD
Bosentan—Loss of consciousness—Capecitabine—kidney cancer	9.69e-05	0.000329	CcSEcCtD
Bosentan—Dyspepsia—Paclitaxel—kidney cancer	9.65e-05	0.000327	CcSEcCtD
Bosentan—Cough—Capecitabine—kidney cancer	9.62e-05	0.000326	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—kidney cancer	9.53e-05	0.000323	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—kidney cancer	9.53e-05	0.000323	CcSEcCtD
Bosentan—Decreased appetite—Paclitaxel—kidney cancer	9.53e-05	0.000323	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—kidney cancer	9.48e-05	0.000321	CcSEcCtD
Bosentan—Gastrointestinal disorder—Paclitaxel—kidney cancer	9.46e-05	0.000321	CcSEcCtD
Bosentan—Fatigue—Paclitaxel—kidney cancer	9.45e-05	0.000321	CcSEcCtD
Bosentan—Diarrhoea—Vincristine—kidney cancer	9.44e-05	0.00032	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—kidney cancer	9.42e-05	0.000319	CcSEcCtD
Bosentan—Asthenia—Gemcitabine—kidney cancer	9.39e-05	0.000319	CcSEcCtD
Bosentan—Arthralgia—Capecitabine—kidney cancer	9.38e-05	0.000318	CcSEcCtD
Bosentan—Chest pain—Capecitabine—kidney cancer	9.38e-05	0.000318	CcSEcCtD
Bosentan—Pain—Paclitaxel—kidney cancer	9.37e-05	0.000318	CcSEcCtD
Bosentan—Constipation—Paclitaxel—kidney cancer	9.37e-05	0.000318	CcSEcCtD
Bosentan—Anxiety—Capecitabine—kidney cancer	9.35e-05	0.000317	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	9.32e-05	0.000316	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—kidney cancer	9.28e-05	0.000315	CcSEcCtD
Bosentan—Discomfort—Capecitabine—kidney cancer	9.27e-05	0.000314	CcSEcCtD
Bosentan—Pruritus—Gemcitabine—kidney cancer	9.26e-05	0.000314	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—kidney cancer	9.22e-05	0.000313	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—kidney cancer	9.2e-05	0.000312	CcSEcCtD
Bosentan—Dry mouth—Capecitabine—kidney cancer	9.18e-05	0.000311	CcSEcCtD
Bosentan—Nausea—Dactinomycin—kidney cancer	9.17e-05	0.000311	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—kidney cancer	9.14e-05	0.00031	CcSEcCtD
Bosentan—Dizziness—Vincristine—kidney cancer	9.13e-05	0.00031	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—kidney cancer	9.09e-05	0.000308	CcSEcCtD
Bosentan—Infestation—Doxorubicin—kidney cancer	9.09e-05	0.000308	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	9.01e-05	0.000306	CcSEcCtD
Bosentan—Oedema—Capecitabine—kidney cancer	8.99e-05	0.000305	CcSEcCtD
Bosentan—Gastrointestinal pain—Paclitaxel—kidney cancer	8.96e-05	0.000304	CcSEcCtD
Bosentan—Diarrhoea—Gemcitabine—kidney cancer	8.96e-05	0.000304	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—kidney cancer	8.94e-05	0.000303	CcSEcCtD
Bosentan—Infection—Capecitabine—kidney cancer	8.94e-05	0.000303	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—kidney cancer	8.86e-05	0.000301	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—kidney cancer	8.86e-05	0.000301	CcSEcCtD
Bosentan—Shock—Capecitabine—kidney cancer	8.85e-05	0.0003	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—kidney cancer	8.84e-05	0.0003	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—kidney cancer	8.84e-05	0.0003	CcSEcCtD
Bosentan—Nervous system disorder—Capecitabine—kidney cancer	8.82e-05	0.000299	CcSEcCtD
Bosentan—Thrombocytopenia—Capecitabine—kidney cancer	8.81e-05	0.000299	CcSEcCtD
Bosentan—ABCB11—Metabolism—PPAT—kidney cancer	8.79e-05	0.0014	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GLIPR1—kidney cancer	8.79e-05	0.0014	CbGpPWpGaD
Bosentan—Tachycardia—Capecitabine—kidney cancer	8.78e-05	0.000298	CcSEcCtD
Bosentan—Vomiting—Vincristine—kidney cancer	8.77e-05	0.000298	CcSEcCtD
Bosentan—Skin disorder—Capecitabine—kidney cancer	8.74e-05	0.000296	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—GRB7—kidney cancer	8.73e-05	0.0014	CbGpPWpGaD
Bosentan—Urticaria—Paclitaxel—kidney cancer	8.71e-05	0.000295	CcSEcCtD
Bosentan—Rash—Vincristine—kidney cancer	8.7e-05	0.000295	CcSEcCtD
Bosentan—Hyperhidrosis—Capecitabine—kidney cancer	8.7e-05	0.000295	CcSEcCtD
Bosentan—Dermatitis—Vincristine—kidney cancer	8.69e-05	0.000295	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	8.68e-05	0.00139	CbGpPWpGaD
Bosentan—Haematuria—Doxorubicin—kidney cancer	8.67e-05	0.000294	CcSEcCtD
Bosentan—Abdominal pain—Paclitaxel—kidney cancer	8.66e-05	0.000294	CcSEcCtD
Bosentan—Body temperature increased—Paclitaxel—kidney cancer	8.66e-05	0.000294	CcSEcCtD
Bosentan—Headache—Vincristine—kidney cancer	8.65e-05	0.000293	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—kidney cancer	8.6e-05	0.000292	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	8.59e-05	0.00137	CbGpPWpGaD
Bosentan—Epistaxis—Doxorubicin—kidney cancer	8.57e-05	0.000291	CcSEcCtD
Bosentan—Anorexia—Capecitabine—kidney cancer	8.57e-05	0.000291	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—kidney cancer	8.53e-05	0.000289	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—SFRP2—kidney cancer	8.48e-05	0.00135	CbGpPWpGaD
Bosentan—Hypotension—Capecitabine—kidney cancer	8.4e-05	0.000285	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.33e-05	0.00133	CbGpPWpGaD
Bosentan—Vomiting—Gemcitabine—kidney cancer	8.32e-05	0.000282	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—kidney cancer	8.31e-05	0.000282	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	8.29e-05	0.00133	CbGpPWpGaD
Bosentan—Rash—Gemcitabine—kidney cancer	8.25e-05	0.00028	CcSEcCtD
Bosentan—Dermatitis—Gemcitabine—kidney cancer	8.25e-05	0.00028	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—ANXA1—kidney cancer	8.24e-05	0.00132	CbGpPWpGaD
Bosentan—Haemoglobin—Doxorubicin—kidney cancer	8.2e-05	0.000278	CcSEcCtD
Bosentan—Headache—Gemcitabine—kidney cancer	8.2e-05	0.000278	CcSEcCtD
Bosentan—Nausea—Vincristine—kidney cancer	8.2e-05	0.000278	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Capecitabine—kidney cancer	8.19e-05	0.000278	CcSEcCtD
Bosentan—ABCB11—Metabolism—FH—kidney cancer	8.17e-05	0.00131	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—APRT—kidney cancer	8.17e-05	0.00131	CbGpPWpGaD
Bosentan—Hepatitis—Doxorubicin—kidney cancer	8.16e-05	0.000277	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—kidney cancer	8.16e-05	0.000277	CcSEcCtD
Bosentan—Insomnia—Capecitabine—kidney cancer	8.14e-05	0.000276	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—kidney cancer	8.12e-05	0.000275	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—ITPR2—kidney cancer	8.12e-05	0.0013	CbGpPWpGaD
Bosentan—Paraesthesia—Capecitabine—kidney cancer	8.08e-05	0.000274	CcSEcCtD
Bosentan—Hypersensitivity—Paclitaxel—kidney cancer	8.08e-05	0.000274	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—kidney cancer	8.06e-05	0.000273	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—kidney cancer	8.04e-05	0.000273	CcSEcCtD
Bosentan—Dyspnoea—Capecitabine—kidney cancer	8.02e-05	0.000272	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—kidney cancer	8e-05	0.000271	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	7.99e-05	0.00128	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTT1—kidney cancer	7.97e-05	0.00127	CbGpPWpGaD
Bosentan—Dyspepsia—Capecitabine—kidney cancer	7.92e-05	0.000269	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	7.89e-05	0.00126	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—POMC—kidney cancer	7.87e-05	0.00126	CbGpPWpGaD
Bosentan—Asthenia—Paclitaxel—kidney cancer	7.86e-05	0.000267	CcSEcCtD
Bosentan—Decreased appetite—Capecitabine—kidney cancer	7.82e-05	0.000265	CcSEcCtD
Bosentan—Nausea—Gemcitabine—kidney cancer	7.78e-05	0.000264	CcSEcCtD
Bosentan—Gastrointestinal disorder—Capecitabine—kidney cancer	7.77e-05	0.000263	CcSEcCtD
Bosentan—Fatigue—Capecitabine—kidney cancer	7.75e-05	0.000263	CcSEcCtD
Bosentan—Pruritus—Paclitaxel—kidney cancer	7.75e-05	0.000263	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—kidney cancer	7.72e-05	0.000262	CcSEcCtD
Bosentan—Constipation—Capecitabine—kidney cancer	7.69e-05	0.000261	CcSEcCtD
Bosentan—Pain—Capecitabine—kidney cancer	7.69e-05	0.000261	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	7.69e-05	0.00123	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GPC3—kidney cancer	7.68e-05	0.00123	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—kidney cancer	7.66e-05	0.00122	CbGpPWpGaD
Bosentan—Eye disorder—Doxorubicin—kidney cancer	7.63e-05	0.000259	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—kidney cancer	7.61e-05	0.000258	CcSEcCtD
Bosentan—Flushing—Doxorubicin—kidney cancer	7.57e-05	0.000257	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—kidney cancer	7.57e-05	0.000257	CcSEcCtD
Bosentan—Diarrhoea—Paclitaxel—kidney cancer	7.5e-05	0.000254	CcSEcCtD
Bosentan—ABCB11—Metabolism—CA2—kidney cancer	7.47e-05	0.00119	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—PTGS1—kidney cancer	7.47e-05	0.00119	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	7.45e-05	0.00119	CbGpPWpGaD
Bosentan—Angiopathy—Doxorubicin—kidney cancer	7.4e-05	0.000251	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—kidney cancer	7.37e-05	0.00025	CcSEcCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	7.37e-05	0.00118	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNA1—kidney cancer	7.36e-05	0.00118	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Capecitabine—kidney cancer	7.36e-05	0.000249	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—kidney cancer	7.35e-05	0.000249	CcSEcCtD
Bosentan—Chills—Doxorubicin—kidney cancer	7.32e-05	0.000248	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—EIF4EBP1—kidney cancer	7.32e-05	0.00117	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HSPB1—kidney cancer	7.32e-05	0.00117	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALAD—kidney cancer	7.28e-05	0.00116	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	7.27e-05	0.00116	CbGpPWpGaD
Bosentan—Dizziness—Paclitaxel—kidney cancer	7.25e-05	0.000246	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—kidney cancer	7.15e-05	0.000243	CcSEcCtD
Bosentan—Urticaria—Capecitabine—kidney cancer	7.15e-05	0.000242	CcSEcCtD
Bosentan—Body temperature increased—Capecitabine—kidney cancer	7.11e-05	0.000241	CcSEcCtD
Bosentan—Abdominal pain—Capecitabine—kidney cancer	7.11e-05	0.000241	CcSEcCtD
Bosentan—ABCB11—Metabolism—ST3GAL2—kidney cancer	7.11e-05	0.00114	CbGpPWpGaD
Bosentan—Erythema—Doxorubicin—kidney cancer	7.1e-05	0.000241	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—kidney cancer	7.1e-05	0.000241	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—kidney cancer	7e-05	0.000237	CcSEcCtD
Bosentan—Vomiting—Paclitaxel—kidney cancer	6.97e-05	0.000236	CcSEcCtD
Bosentan—ABCB11—Metabolism—ALDH1A1—kidney cancer	6.95e-05	0.00111	CbGpPWpGaD
Bosentan—Rash—Paclitaxel—kidney cancer	6.91e-05	0.000234	CcSEcCtD
Bosentan—Dermatitis—Paclitaxel—kidney cancer	6.9e-05	0.000234	CcSEcCtD
Bosentan—Back pain—Doxorubicin—kidney cancer	6.87e-05	0.000233	CcSEcCtD
Bosentan—Headache—Paclitaxel—kidney cancer	6.87e-05	0.000233	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	6.85e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP2—kidney cancer	6.83e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKAP13—kidney cancer	6.83e-05	0.00109	CbGpPWpGaD
Bosentan—Muscle spasms—Doxorubicin—kidney cancer	6.83e-05	0.000232	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PSMD7—kidney cancer	6.8e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TSC1—kidney cancer	6.8e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ANXA1—kidney cancer	6.8e-05	0.00109	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.76e-05	0.00108	CbGpPWpGaD
Bosentan—Vision blurred—Doxorubicin—kidney cancer	6.7e-05	0.000227	CcSEcCtD
Bosentan—ABCB11—Metabolism—PGK1—kidney cancer	6.66e-05	0.00106	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC5A3—kidney cancer	6.66e-05	0.00106	CbGpPWpGaD
Bosentan—Hypersensitivity—Capecitabine—kidney cancer	6.63e-05	0.000225	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	6.59e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FLT1—kidney cancer	6.59e-05	0.00105	CbGpPWpGaD
Bosentan—Anaemia—Doxorubicin—kidney cancer	6.57e-05	0.000223	CcSEcCtD
Bosentan—ABCB11—Metabolism—LDHB—kidney cancer	6.53e-05	0.00104	CbGpPWpGaD
Bosentan—Nausea—Paclitaxel—kidney cancer	6.51e-05	0.000221	CcSEcCtD
Bosentan—Asthenia—Capecitabine—kidney cancer	6.45e-05	0.000219	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—kidney cancer	6.38e-05	0.000216	CcSEcCtD
Bosentan—Syncope—Doxorubicin—kidney cancer	6.37e-05	0.000216	CcSEcCtD
Bosentan—Pruritus—Capecitabine—kidney cancer	6.36e-05	0.000216	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—kidney cancer	6.36e-05	0.000216	CcSEcCtD
Bosentan—Palpitations—Doxorubicin—kidney cancer	6.28e-05	0.000213	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—GRB7—kidney cancer	6.25e-05	0.000999	CbGpPWpGaD
Bosentan—Loss of consciousness—Doxorubicin—kidney cancer	6.24e-05	0.000212	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—POMC—kidney cancer	6.21e-05	0.000993	CbGpPWpGaD
Bosentan—Cough—Doxorubicin—kidney cancer	6.2e-05	0.00021	CcSEcCtD
Bosentan—Diarrhoea—Capecitabine—kidney cancer	6.15e-05	0.000209	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PAK1—kidney cancer	6.11e-05	0.000976	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JUNB—kidney cancer	6.11e-05	0.000976	CbGpPWpGaD
Bosentan—Arthralgia—Doxorubicin—kidney cancer	6.05e-05	0.000205	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—kidney cancer	6.05e-05	0.000205	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—kidney cancer	6.03e-05	0.000204	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.01e-05	0.000204	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—kidney cancer	5.98e-05	0.000203	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	5.98e-05	0.000955	CbGpPWpGaD
Bosentan—Dizziness—Capecitabine—kidney cancer	5.95e-05	0.000202	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—kidney cancer	5.92e-05	0.000201	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—ITPR2—kidney cancer	5.81e-05	0.000928	CbGpPWpGaD
Bosentan—Anaphylactic shock—Doxorubicin—kidney cancer	5.8e-05	0.000197	CcSEcCtD
Bosentan—Oedema—Doxorubicin—kidney cancer	5.8e-05	0.000197	CcSEcCtD
Bosentan—Infection—Doxorubicin—kidney cancer	5.76e-05	0.000195	CcSEcCtD
Bosentan—Vomiting—Capecitabine—kidney cancer	5.72e-05	0.000194	CcSEcCtD
Bosentan—Shock—Doxorubicin—kidney cancer	5.7e-05	0.000193	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—kidney cancer	5.69e-05	0.000193	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—kidney cancer	5.68e-05	0.000193	CcSEcCtD
Bosentan—Rash—Capecitabine—kidney cancer	5.67e-05	0.000192	CcSEcCtD
Bosentan—Dermatitis—Capecitabine—kidney cancer	5.67e-05	0.000192	CcSEcCtD
Bosentan—ABCB11—Metabolism—CA9—kidney cancer	5.66e-05	0.000905	CbGpPWpGaD
Bosentan—Tachycardia—Doxorubicin—kidney cancer	5.66e-05	0.000192	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—POMC—kidney cancer	5.64e-05	0.000902	CbGpPWpGaD
Bosentan—Headache—Capecitabine—kidney cancer	5.63e-05	0.000191	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—kidney cancer	5.63e-05	0.000191	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—kidney cancer	5.61e-05	0.00019	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	5.54e-05	0.000885	CbGpPWpGaD
Bosentan—Anorexia—Doxorubicin—kidney cancer	5.53e-05	0.000187	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—GSTP1—kidney cancer	5.52e-05	0.000883	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	5.5e-05	0.000878	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	5.45e-05	0.000871	CbGpPWpGaD
Bosentan—Hypotension—Doxorubicin—kidney cancer	5.42e-05	0.000184	CcSEcCtD
Bosentan—Nausea—Capecitabine—kidney cancer	5.34e-05	0.000181	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—kidney cancer	5.28e-05	0.000179	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CTNNA1—kidney cancer	5.27e-05	0.000842	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTT1—kidney cancer	5.26e-05	0.00084	CbGpPWpGaD
Bosentan—Insomnia—Doxorubicin—kidney cancer	5.24e-05	0.000178	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—EIF4EBP1—kidney cancer	5.24e-05	0.000837	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HSPB1—kidney cancer	5.24e-05	0.000837	CbGpPWpGaD
Bosentan—Paraesthesia—Doxorubicin—kidney cancer	5.21e-05	0.000177	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—kidney cancer	5.17e-05	0.000175	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—kidney cancer	5.15e-05	0.000175	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—kidney cancer	5.1e-05	0.000173	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—GSTM1—kidney cancer	5.08e-05	0.000811	CbGpPWpGaD
Bosentan—Decreased appetite—Doxorubicin—kidney cancer	5.04e-05	0.000171	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	5.01e-05	0.0008	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.01e-05	0.00017	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—kidney cancer	5e-05	0.00017	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—IGF2—kidney cancer	4.99e-05	0.000798	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN2B—kidney cancer	4.97e-05	0.000794	CbGpPWpGaD
Bosentan—Constipation—Doxorubicin—kidney cancer	4.96e-05	0.000168	CcSEcCtD
Bosentan—Pain—Doxorubicin—kidney cancer	4.96e-05	0.000168	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—PTGS1—kidney cancer	4.93e-05	0.000787	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSMD7—kidney cancer	4.87e-05	0.000778	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TSC1—kidney cancer	4.87e-05	0.000778	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ANXA1—kidney cancer	4.87e-05	0.000778	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1R—kidney cancer	4.83e-05	0.000771	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CRABP1—kidney cancer	4.82e-05	0.00077	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	4.81e-05	0.000769	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	4.75e-05	0.000759	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—kidney cancer	4.74e-05	0.000161	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—FLT1—kidney cancer	4.72e-05	0.000753	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—RAF1—kidney cancer	4.65e-05	0.000743	CbGpPWpGaD
Bosentan—Urticaria—Doxorubicin—kidney cancer	4.61e-05	0.000156	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—IL2—kidney cancer	4.59e-05	0.000734	CbGpPWpGaD
Bosentan—Body temperature increased—Doxorubicin—kidney cancer	4.58e-05	0.000155	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—kidney cancer	4.58e-05	0.000155	CcSEcCtD
Bosentan—ABCB11—Metabolism—ITPR2—kidney cancer	4.48e-05	0.000715	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	4.46e-05	0.000712	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—POMC—kidney cancer	4.45e-05	0.000711	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JUNB—kidney cancer	4.37e-05	0.000698	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PAK1—kidney cancer	4.37e-05	0.000698	CbGpPWpGaD
Bosentan—Hypersensitivity—Doxorubicin—kidney cancer	4.27e-05	0.000145	CcSEcCtD
Bosentan—CYP2C9—Metabolism—ACY1—kidney cancer	4.23e-05	0.000677	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL2—kidney cancer	4.17e-05	0.000666	CbGpPWpGaD
Bosentan—Asthenia—Doxorubicin—kidney cancer	4.16e-05	0.000141	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.13e-05	0.00066	CbGpPWpGaD
Bosentan—Pruritus—Doxorubicin—kidney cancer	4.1e-05	0.000139	CcSEcCtD
Bosentan—ABCB11—Metabolism—ACHE—kidney cancer	4.08e-05	0.000652	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTT1—kidney cancer	4.08e-05	0.000652	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—POMC—kidney cancer	4.04e-05	0.000645	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HIF1A—kidney cancer	3.97e-05	0.000635	CbGpPWpGaD
Bosentan—Diarrhoea—Doxorubicin—kidney cancer	3.97e-05	0.000135	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TSC2—kidney cancer	3.96e-05	0.000634	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SCARB1—kidney cancer	3.86e-05	0.000618	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—kidney cancer	3.83e-05	0.00013	CcSEcCtD
Bosentan—ABCB11—Metabolism—PTGS1—kidney cancer	3.83e-05	0.000611	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KDR—kidney cancer	3.8e-05	0.000607	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PSMD7—kidney cancer	3.75e-05	0.0006	CbGpPWpGaD
Bosentan—Vomiting—Doxorubicin—kidney cancer	3.69e-05	0.000125	CcSEcCtD
Bosentan—Rash—Doxorubicin—kidney cancer	3.66e-05	0.000124	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—kidney cancer	3.65e-05	0.000124	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—GSTP1—kidney cancer	3.64e-05	0.000582	CbGpPWpGaD
Bosentan—Headache—Doxorubicin—kidney cancer	3.63e-05	0.000123	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.61e-05	0.000577	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PDHB—kidney cancer	3.6e-05	0.000575	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	3.59e-05	0.000574	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—POMC—kidney cancer	3.59e-05	0.000573	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF2—kidney cancer	3.57e-05	0.000571	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN2B—kidney cancer	3.56e-05	0.000569	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—BCHE—kidney cancer	3.56e-05	0.000568	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC5A5—kidney cancer	3.51e-05	0.000561	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KIT—kidney cancer	3.5e-05	0.000559	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—APC—kidney cancer	3.5e-05	0.000559	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1R—kidney cancer	3.45e-05	0.000552	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—kidney cancer	3.44e-05	0.000117	CcSEcCtD
Bosentan—ABCB11—Metabolism—SLC2A1—kidney cancer	3.39e-05	0.000542	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CCBL1—kidney cancer	3.38e-05	0.000541	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK3—kidney cancer	3.35e-05	0.000536	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTM1—kidney cancer	3.35e-05	0.000535	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—POMC—kidney cancer	3.33e-05	0.000533	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—RAF1—kidney cancer	3.33e-05	0.000532	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	3.3e-05	0.000528	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.29e-05	0.000526	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—BRAF—kidney cancer	3.29e-05	0.000526	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—kidney cancer	3.29e-05	0.000525	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK1—kidney cancer	3.19e-05	0.00051	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	3.17e-05	0.000507	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	3.13e-05	0.0005	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	3.06e-05	0.000489	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—kidney cancer	3.05e-05	0.000487	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—kidney cancer	3.01e-05	0.000482	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL2—kidney cancer	2.98e-05	0.000477	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.93e-05	0.000469	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPAT—kidney cancer	2.93e-05	0.000469	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.9e-05	0.000463	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.87e-05	0.000459	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.87e-05	0.000458	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HIF1A—kidney cancer	2.84e-05	0.000455	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TSC2—kidney cancer	2.84e-05	0.000453	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTP1—kidney cancer	2.83e-05	0.000452	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACY1—kidney cancer	2.79e-05	0.000446	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—kidney cancer	2.77e-05	0.000442	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RAF1—kidney cancer	2.75e-05	0.000439	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—RELA—kidney cancer	2.74e-05	0.000437	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—APRT—kidney cancer	2.73e-05	0.000436	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FH—kidney cancer	2.73e-05	0.000436	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KDR—kidney cancer	2.72e-05	0.000435	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—kidney cancer	2.72e-05	0.000434	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MTOR—kidney cancer	2.68e-05	0.000429	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ABCB1—kidney cancer	2.68e-05	0.000428	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.67e-05	0.000426	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTM1—kidney cancer	2.6e-05	0.000416	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPC3—kidney cancer	2.57e-05	0.00041	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1B—kidney cancer	2.52e-05	0.000402	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—APC—kidney cancer	2.51e-05	0.0004	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KIT—kidney cancer	2.51e-05	0.0004	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA2—kidney cancer	2.5e-05	0.000399	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP1A1—kidney cancer	2.47e-05	0.000394	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—kidney cancer	2.46e-05	0.000394	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALAD—kidney cancer	2.43e-05	0.000389	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—kidney cancer	2.4e-05	0.000384	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK3—kidney cancer	2.4e-05	0.000383	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JUN—kidney cancer	2.4e-05	0.000383	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—POMC—kidney cancer	2.39e-05	0.000381	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNB1—kidney cancer	2.38e-05	0.00038	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PDHB—kidney cancer	2.37e-05	0.000379	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ST3GAL2—kidney cancer	2.37e-05	0.000379	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—POMC—kidney cancer	2.37e-05	0.000378	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—BRAF—kidney cancer	2.36e-05	0.000376	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDH1A1—kidney cancer	2.32e-05	0.000371	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—kidney cancer	2.32e-05	0.00037	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK1—kidney cancer	2.28e-05	0.000365	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CCBL1—kidney cancer	2.23e-05	0.000357	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PGK1—kidney cancer	2.22e-05	0.000355	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A3—kidney cancer	2.22e-05	0.000355	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—kidney cancer	2.18e-05	0.000349	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—LDHB—kidney cancer	2.18e-05	0.000349	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—kidney cancer	2.16e-05	0.000345	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—kidney cancer	2.09e-05	0.000335	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.03e-05	0.000324	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—kidney cancer	1.98e-05	0.000317	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK3—kidney cancer	1.98e-05	0.000317	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RAF1—kidney cancer	1.97e-05	0.000314	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RELA—kidney cancer	1.96e-05	0.000313	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—kidney cancer	1.95e-05	0.000311	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.94e-05	0.000309	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPAT—kidney cancer	1.94e-05	0.000309	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—kidney cancer	1.93e-05	0.000308	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MTOR—kidney cancer	1.92e-05	0.000307	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA9—kidney cancer	1.89e-05	0.000302	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK1—kidney cancer	1.88e-05	0.000301	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.85e-05	0.000295	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—POMC—kidney cancer	1.84e-05	0.000294	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—kidney cancer	1.8e-05	0.000288	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FH—kidney cancer	1.8e-05	0.000288	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—APRT—kidney cancer	1.8e-05	0.000288	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—kidney cancer	1.78e-05	0.000284	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—kidney cancer	1.76e-05	0.000282	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—kidney cancer	1.72e-05	0.000275	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JUN—kidney cancer	1.72e-05	0.000274	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—kidney cancer	1.7e-05	0.000272	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPC3—kidney cancer	1.69e-05	0.00027	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—kidney cancer	1.66e-05	0.000265	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA2—kidney cancer	1.65e-05	0.000263	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—kidney cancer	1.64e-05	0.000261	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CRABP1—kidney cancer	1.61e-05	0.000257	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALAD—kidney cancer	1.6e-05	0.000256	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—kidney cancer	1.58e-05	0.000253	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.57e-05	0.00025	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.53e-05	0.000244	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—kidney cancer	1.5e-05	0.000239	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ITPR2—kidney cancer	1.49e-05	0.000239	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PGK1—kidney cancer	1.47e-05	0.000234	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.47e-05	0.000234	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—kidney cancer	1.47e-05	0.000234	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—LDHB—kidney cancer	1.44e-05	0.00023	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK3—kidney cancer	1.42e-05	0.000227	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—kidney cancer	1.38e-05	0.00022	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.38e-05	0.00022	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—kidney cancer	1.36e-05	0.000218	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ACHE—kidney cancer	1.36e-05	0.000218	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK1—kidney cancer	1.35e-05	0.000216	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SCARB1—kidney cancer	1.29e-05	0.000206	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—kidney cancer	1.28e-05	0.000204	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS1—kidney cancer	1.28e-05	0.000204	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—kidney cancer	1.27e-05	0.000204	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PSMD7—kidney cancer	1.25e-05	0.0002	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA9—kidney cancer	1.25e-05	0.000199	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BCHE—kidney cancer	1.19e-05	0.00019	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.17e-05	0.000187	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—kidney cancer	1.17e-05	0.000187	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.13e-05	0.000181	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—kidney cancer	1.13e-05	0.000181	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.1e-05	0.000176	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CRABP1—kidney cancer	1.06e-05	0.000169	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ITPR2—kidney cancer	9.86e-06	0.000158	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.59e-06	0.000153	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—kidney cancer	9.45e-06	0.000151	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—kidney cancer	9.02e-06	0.000144	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACHE—kidney cancer	8.99e-06	0.000144	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—kidney cancer	8.99e-06	0.000144	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—kidney cancer	8.94e-06	0.000143	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—kidney cancer	8.68e-06	0.000139	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SCARB1—kidney cancer	8.51e-06	0.000136	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS1—kidney cancer	8.42e-06	0.000135	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PSMD7—kidney cancer	8.26e-06	0.000132	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1A1—kidney cancer	8.23e-06	0.000132	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BCHE—kidney cancer	7.83e-06	0.000125	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A5—kidney cancer	7.74e-06	0.000124	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A1—kidney cancer	7.47e-06	0.000119	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.76e-06	0.000108	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—kidney cancer	6.23e-06	9.96e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—POMC—kidney cancer	6.14e-06	9.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—kidney cancer	5.9e-06	9.43e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—kidney cancer	5.73e-06	9.15e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1A1—kidney cancer	5.43e-06	8.67e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—kidney cancer	4.89e-06	7.82e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—kidney cancer	4.27e-06	6.82e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—POMC—kidney cancer	4.05e-06	6.47e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—kidney cancer	3.23e-06	5.16e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—kidney cancer	3.01e-06	4.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—kidney cancer	2.82e-06	4.5e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.99e-06	3.17e-05	CbGpPWpGaD
